Nebenwirkungen · Gencebok
Gencebok 10 mg/ml solution for infusion · Abschnitt 4.8 · PDF-Seite 7
HOS-147399 · Präparat HOS-099648
Caffeine may suppress erythropoietin synthesis and hence reduce haemoglobin concentration with prolonged treatment. Transient falls in thyroxine (T4) have been recorded in infants at the start of therapy but these are not sustained with maintained therapy. Available evidence does not indicate any adverse long-term reactions of neonatal caffeine therapy as regards neurodevelopmental outcome, failure to thrive or on the cardiovascular, gastrointestinal or endocrine systems. Caffeine does not appear to aggravate cerebral hypoxia or to exacerbate any resulting damage, although the possibility cannot be ruled out.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-12T11:47:00Z · SHA-256 6e3fcdb632e35a419e60a0205279199521acdd7f49db6bbb54b87cd49828401f · Passage 29149581d21775655f2de57073f577b3811733bd105c7eebee9fdfec0686033d · Zeichen 4212–4828 im Abschnitt